This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $52.48 in the latest trading session, marking a -1.11% move from the prior day.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance
by Zacks Equity Research
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon
by Zacks Equity Research
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
The Zacks Analyst Blog Highlights: NVIDIA, Salesforce, AstraZeneca, JPMorgan and Chevron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Salesforce, AstraZeneca, JPMorgan and Chevron
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
Top Analyst Reports for NVIDIA, salesforce & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), salesforce.com (CRM) and AstraZeneca (AZN).
Astrazeneca (AZN) Stock Moves -1.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $52.44, marking a -1.11% move from the previous day.
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
Moderna Gets Consent to File MAA for Coronavirus Vaccine in EU
by Zacks Equity Research
Moderna (MRNA) gets permission from the European Medicines Agency to submit a marketing authorization application for mRNA-1273, its vaccine candidate against COVID-19.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Stock Market News for Oct 14, 2020
by Zacks Equity Research
Wall Street closed lower on Tuesday due to uncertainty on second round of coronavirus-aid package.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
5 Must-Buy Blue Chip Stocks to Remain Safe in October
by Nalak Das
It will be prudent to invest in Dow stocks with a favorable Zacks Rank that are likely to provide solid returns in the near term.
Sanofi's Dupixent Meets All Goals in Asthma Study for Children
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.
J&J's Coronavirus Vaccine Studies Paused Post Adverse Event
by Zacks Equity Research
J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $55.27, moving +1.01% from the previous trading session.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
by Zacks Equity Research
Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.
Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.